Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bio-Rad Laboratories stock

Own Bio-Rad Laboratories stock in just a few minutes.

Posted

Fact checked

Bio-Rad Laboratories, Inc is a medical devices business based in the US. Bio-Rad Laboratories shares (BIO) are listed on the NYSE and all prices are listed in US Dollars. Bio-Rad Laboratories employs 8,000 staff and has a trailing 12-month revenue of around USD$2.3 billion.

How to buy shares in Bio-Rad Laboratories

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Bio-Rad Laboratories. Find the stock by name or ticker symbol: BIO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Bio-Rad Laboratories reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Bio-Rad Laboratories, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Bio-Rad Laboratories. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Bio-Rad Laboratories share price

Use our graph to track the performance of BIO stocks over time.

Bio-Rad Laboratories shares at a glance

Information last updated 2020-10-20.
52-week range USD$309.3801 - USD$573.79
50-day moving average USD$522.0289
200-day moving average USD$482.8651
Wall St. target price USD$603.75
PE ratio 8.6277
Dividend yield N/A (0%)
Earnings per share (TTM) USD$64.502

Buy Bio-Rad Laboratories shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Bio-Rad Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Bio-Rad Laboratories under- or over-valued?

Valuing Bio-Rad Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Rad Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bio-Rad Laboratories's P/E ratio

Bio-Rad Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Bio-Rad Laboratories shares trade at around 9x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Bio-Rad Laboratories's PEG ratio

Bio-Rad Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.42. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Rad Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Bio-Rad Laboratories's EBITDA

Bio-Rad Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$409 million.

The EBITDA is a measure of a Bio-Rad Laboratories's overall financial performance and is widely used to measure a its profitability.

Bio-Rad Laboratories financials

Revenue TTM USD$2.3 billion
Operating margin TTM 11.88%
Gross profit TTM USD$1.3 billion
Return on assets TTM 1.92%
Return on equity TTM 30.33%
Profit margin 84.89%
Book value $247.77
Market capitalisation USD$16.3 billion

TTM: trailing 12 months

Shorting Bio-Rad Laboratories shares

There are currently 359,955 Bio-Rad Laboratories shares held short by investors – that's known as Bio-Rad Laboratories's "short interest". This figure is 35.5% down from 557,705 last month.

There are a few different ways that this level of interest in shorting Bio-Rad Laboratories shares can be evaluated.

Bio-Rad Laboratories's "short interest ratio" (SIR)

Bio-Rad Laboratories's "short interest ratio" (SIR) is the quantity of Bio-Rad Laboratories shares currently shorted divided by the average quantity of Bio-Rad Laboratories shares traded daily (recently around 167420.93023256). Bio-Rad Laboratories's SIR currently stands at 2.15. In other words for every 100,000 Bio-Rad Laboratories shares traded daily on the market, roughly 2150 shares are currently held short.

However Bio-Rad Laboratories's short interest can also be evaluated against the total number of Bio-Rad Laboratories shares, or, against the total number of tradable Bio-Rad Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bio-Rad Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Bio-Rad Laboratories shares in existence, roughly 10 shares are currently held short) or 0.0168% of the tradable shares (for every 100,000 tradable Bio-Rad Laboratories shares, roughly 17 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bio-Rad Laboratories.

Find out more about how you can short Bio-Rad Laboratories stock.

Bio-Rad Laboratories's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bio-Rad Laboratories.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Bio-Rad Laboratories's total ESG risk score

Total ESG risk: 23.57

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bio-Rad Laboratories's overall score of 23.57 (as at 10/01/2020) is pretty good – landing it in it in the 28th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Bio-Rad Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Bio-Rad Laboratories's environmental score

Environmental score: 6.03/100

Bio-Rad Laboratories's environmental score of 6.03 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Bio-Rad Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Bio-Rad Laboratories's social score

Social score: 16.8/100

Bio-Rad Laboratories's social score of 16.8 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Bio-Rad Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Bio-Rad Laboratories's governance score

Governance score: 10.75/100

Bio-Rad Laboratories's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Bio-Rad Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Bio-Rad Laboratories's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Bio-Rad Laboratories scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bio-Rad Laboratories has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Bio-Rad Laboratories, Inc was last rated for ESG on: 2020-10-01.

Total ESG score 23.57
Total ESG percentile 27.74
Environmental score 6.03
Environmental score percentile 6
Social score 16.8
Social score percentile 6
Governance score 10.75
Governance score percentile 6
Level of controversy 2

Bio-Rad Laboratories share dividends

We're not expecting Bio-Rad Laboratories to pay a dividend over the next 12 months.

Have Bio-Rad Laboratories's shares ever split?

Bio-Rad Laboratories's shares were split on a 2:1 basis on 8 March 2002. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Bio-Rad Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Bio-Rad Laboratories shares which in turn could have impacted Bio-Rad Laboratories's share price.

Bio-Rad Laboratories share price volatility

Over the last 12 months, Bio-Rad Laboratories's shares have ranged in value from as little as $309.3801 up to $573.79. A popular way to gauge a stock's volatility is its "beta".

BIO.US volatility(beta: 1.01)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bio-Rad Laboratories's is 1.0061. This would suggest that Bio-Rad Laboratories's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Bio-Rad Laboratories overview

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site